InflaRx Overview

  • Founded
  • 2007
Founded
  • Status
  • Public
  • Employees
  • 49
Employees
  • Stock Symbol
  • IFRX
Stock Symbol
  • Share Price
  • $3.21
  • (As of Friday Closing)

InflaRx General Information

Description

InflaRx NV is a clinical-stage biopharmaceutical company that is focused on applying proprietary anti-C5a technology to discover and develop specific inhibitors of the complement activation factor known as C5a. The lead product candidate of the company is IFX-1, which is developed for the treatment of Hidradenitis Suppurativa, a rare and chronic debilitating systemic inflammatory skin disease. The company's proprietary anti-C5a technology is an inflammatory mediator involved in the progression of a variety of autoimmune and other inflammatory diseases. It is also developing IFX-1 for the treatment of AAV, a life-threatening autoimmune disease associated with powerful inflammatory flares that impair kidney function and lead to fatal organ dysfunction.

Contact Information

Website
www.InflaRx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Stock Exchange
NAS
Primary Office
  • Winzerlaer Street 2
  • 07745 Jena
  • Germany
+49 03641 000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

InflaRx Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.21 $3.19 $2.66 - $6.88 $141M 44.2M 292K -$1.32

InflaRx Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 71,869 30,732 (44,842) 813,999
Revenue 0 0 0 0
EBITDA (36,864) (38,908) (62,029) (37,554)
Net Income (37,136) (38,738) (59,616) (35,183)
Total Assets 172,620 108,503 136,187 182,126
Total Debt 549 688 948 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

InflaRx Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore InflaRx‘s full profile, request access.

Request a free trial

InflaRx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
InflaRx NV is a clinical-stage biopharmaceutical company that is focused on applying proprietary anti-C5a technology to
Drug Discovery
Jena, Germany
49 As of 2020
00000
000000 - 000 00000

00000000

equat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla
0000 000000000
Rockville, MD
000 As of 0000
00000
000000000 00000

000000 0

uat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pa
0000 000000000
Cambridge, MA
00 As of 0000
00000
00000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

InflaRx Competitors (21)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
MacroGenics Formerly VC-backed Rockville, MD 000 00000 000000000 00000
000000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000 00000
00000 00000 000000 Venture Capital-Backed Geneva, Switzerland 00 00000 0000000000 0 00000
000 (0000000000000 Formerly VC-backed San Francisco, CA 000 00000 000000 - 000 00000
0000000 Formerly VC-backed Waltham, MA 000 00000 000000 - 000 00000
You’re viewing 5 of 21 competitors. Get the full list »

InflaRx Executive Team (7)

Name Title Board Seat Contact Info
Niels Riedemann Ph.D Chief Executive Officer & Board Member
Thomas Taapken Ph.D Chief Financial Officer, Finance
Jordan Zwick Chief Strategy Officer, Strategy
Renfeng Guo MD Chief Scientific Officer & Board Member
Othmar Zenker MD Chief Medical Officer
You’re viewing 5 of 7 executive team members. Get the full list »

InflaRx Board Members (8)

Name Representing Role Since
Anthony Gibney InflaRx Board Member 000 0000
Nicolas Fulpius Self Chairman & Board Member 000 0000
Niels Riedemann Ph.D InflaRx Chief Executive Officer & Board Member 000 0000
Renfeng Guo MD InflaRx Chief Scientific Officer & Board Member 000 0000
Richard Brudnick Self Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

InflaRx Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

InflaRx Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore InflaRx‘s full profile, request access.

Request a free trial